Back to News
Market Impact: 0.15
Immuron to launch PROIBS® in the United States
Source: globenewswire.com
Healthcare & BiotechProduct LaunchesCompany Fundamentals
Immuron (ASX: IMC; NASDAQ: IMRN) executed an exclusive U.S. distribution agreement for PROIBS® with Calmino group AB. PROIBS® was launched in Australia during FY26, and the deal extends the product’s commercial reach into the U.S., which should be modestly supportive for revenue visibility despite limited disclosed financial terms.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
IMRN0.45
More News
- Indonesian stocks plunge to six-year low as MSCI downgrade fears mount
- China's CXMT sees shares drop over 6% as investors look past chipmaker's profit turnaround
- Australia’s Cleanaway agrees to $6.5 bln EQT buyout bid; shares surge
- India’s Finance Minister blames easy exits and excess liquidity for equity market's underperformance
- Zoom and big financial firms add ‘Proof of Human’ badges from Sam Altman’s World to stop fraud and deep fakes
- Daiichi Life Offers to Buy Remainder of Australia’s Challenger
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Run Cost-Controlled Financial Research in AllMind Agent Studio
- State of Public Markets, June 2026: Higher for Longer Meets the AI Supercycle